Stempoint Capital
Latest statistics and disclosures from Stempoint Capital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are ROIV, QURE, IMVT, SRRK, DNLI, and represent 34.17% of Stempoint Capital's stock portfolio.
- Added to shares of these 10 stocks: ROIV (+$41M), BHVN (+$20M), DNLI (+$15M), ARGX (+$9.2M), WVE (+$8.9M), RVMD (+$8.7M), SRRK (+$8.1M), XENE (+$7.7M), IMVT (+$7.1M), CELC (+$6.8M).
- Started 43 new stock positions in ASMB, RVMD, JAZZ, TRVI, WHWK, ARGX, XFOR, OCUL, ARKG, QQQ.
- Reduced shares in these 10 stocks: MDGL (-$20M), MLYS (-$18M), ACLX (-$16M), MRUS (-$14M), SNDX (-$14M), CDTX (-$11M), CNTA (-$11M), GERN (-$9.8M), LEGN (-$9.6M), ZLAB (-$8.8M).
- Sold out of its positions in APGE, EYPT, GERN, JANX, LEGN, LENZ, NUVL, PRAX, REGN, VRNA. ZLAB, HLXB, MRUS.
- Stempoint Capital was a net buyer of stock by $56M.
- Stempoint Capital has $517M in assets under management (AUM), dropping by 61.01%.
- Central Index Key (CIK): 0001952142
Tip: Access up to 7 years of quarterly data
Positions held by Stempoint Capital consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Stempoint Capital
Stempoint Capital holds 80 positions in its portfolio as reported in the September 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Roivant Sciences SHS (ROIV) | 12.3 | $64M | +176% | 4.2M | 15.13 |
|
| Uniqure Nv SHS (QURE) | 5.9 | $31M | -8% | 522k | 58.37 |
|
| Immunovant (IMVT) | 5.7 | $30M | +31% | 1.8M | 16.12 |
|
| Scholar Rock Hldg Corp (SRRK) | 5.4 | $28M | +40% | 745k | 37.24 |
|
| Denali Therapeutics (DNLI) | 4.9 | $25M | +145% | 1.7M | 14.52 |
|
| Syndax Pharmaceuticals (SNDX) | 4.4 | $23M | -38% | 1.5M | 15.38 |
|
| Biohaven (BHVN) | 4.4 | $23M | +756% | 1.5M | 15.01 |
|
| Centessa Pharmaceuticals Sponsored Ads (CNTA) | 3.9 | $20M | -34% | 828k | 24.25 |
|
| Wave Life Sciences SHS (WVE) | 3.0 | $15M | +134% | 2.1M | 7.32 |
|
| Cidara Therapeutics Com New (CDTX) | 2.8 | $15M | -42% | 152k | 95.76 |
|
| Abivax Sa Sponsored Ads (ABVX) | 2.7 | $14M | +89% | 166k | 84.90 |
|
| Ideaya Biosciences (IDYA) | 2.0 | $10M | +124% | 372k | 27.21 |
|
| Rhythm Pharmaceuticals (RYTM) | 1.8 | $9.2M | -48% | 91k | 100.99 |
|
| Argenx Se Sponsored Adr (ARGX) | 1.8 | $9.2M | NEW | 13k | 737.56 |
|
| Surrozen Com New (SRZN) | 1.8 | $9.2M | +3% | 714k | 12.88 |
|
| Vistagen Therapeutics Ord (VTGN) | 1.7 | $8.8M | +3% | 2.5M | 3.55 |
|
| Revolution Medicines (RVMD) | 1.7 | $8.7M | NEW | 185k | 46.70 |
|
| Rezolute Com New (RZLT) | 1.7 | $8.6M | +42% | 918k | 9.40 |
|
| Gh Research Ordinary Shares (GHRS) | 1.5 | $7.8M | +440% | 545k | 14.30 |
|
| Arcutis Biotherapeutics (ARQT) | 1.5 | $7.8M | +100% | 412k | 18.85 |
|
| Xenon Pharmaceuticals (XENE) | 1.5 | $7.7M | NEW | 192k | 40.15 |
|
| Alkermes SHS (ALKS) | 1.4 | $7.2M | -31% | 242k | 30.00 |
|
| Celcuity (CELC) | 1.3 | $6.8M | NEW | 137k | 49.40 |
|
| Bridgebio Pharma (BBIO) | 1.3 | $6.6M | +133% | 127k | 51.94 |
|
| Akero Therapeutics (AKRO) | 1.3 | $6.5M | +17% | 137k | 47.48 |
|
| Insmed Com Par $.01 (INSM) | 1.2 | $6.3M | -29% | 43k | 143.98 |
|
| Dyne Therapeutics (DYN) | 1.2 | $6.0M | NEW | 475k | 12.65 |
|
| Mineralys Therapeutics (MLYS) | 1.2 | $6.0M | -74% | 158k | 37.92 |
|
| Jazz Pharmaceuticals Shs Usd (JAZZ) | 1.0 | $5.1M | NEW | 39k | 131.80 |
|
| Avidity Biosciences Ord (RNA) | 1.0 | $5.0M | NEW | 114k | 43.57 |
|
| Newamsterdam Pharma Company Ordinary Shares (NAMS) | 0.8 | $4.3M | 151k | 28.44 |
|
|
| Ocular Therapeutix (OCUL) | 0.8 | $4.2M | NEW | 360k | 11.69 |
|
| Madrigal Pharmaceuticals (MDGL) | 0.7 | $3.8M | -84% | 8.2k | 458.66 |
|
| Amylyx Pharmaceuticals (AMLX) | 0.7 | $3.8M | NEW | 277k | 13.59 |
|
| Incyte Corporation (INCY) | 0.7 | $3.7M | NEW | 44k | 84.81 |
|
| Structure Therapeutics Sponsored Ads (GPCR) | 0.7 | $3.6M | NEW | 129k | 28.00 |
|
| Trevi Therapeutics (TRVI) | 0.6 | $3.2M | NEW | 351k | 9.15 |
|
| Protagonist Therapeutics (PTGX) | 0.6 | $3.2M | +185% | 48k | 66.43 |
|
| Nektar Therapeutics Com New (NKTR) | 0.6 | $3.0M | NEW | 53k | 56.90 |
|
| Ascendis Pharma A/s Sponsored Adr (ASND) | 0.6 | $3.0M | NEW | 15k | 198.81 |
|
| Tectonic Therapeutic (TECX) | 0.6 | $3.0M | +372% | 189k | 15.69 |
|
| Harrow Health (HROW) | 0.5 | $2.8M | NEW | 58k | 48.18 |
|
| Taysha Gene Therapies Com Shs (TSHA) | 0.5 | $2.7M | -30% | 840k | 3.27 |
|
| Equillium (EQ) | 0.5 | $2.7M | NEW | 1.9M | 1.43 |
|
| United Therapeutics Corporation (UTHR) | 0.5 | $2.6M | NEW | 6.3k | 419.21 |
|
| Cg Oncology (CGON) | 0.5 | $2.5M | NEW | 63k | 40.28 |
|
| Invesco Qqq Tr Unit Ser 1 (QQQ) | 0.4 | $2.3M | NEW | 3.8k | 600.37 |
|
| Bridgebio Oncology Therapeut Com New | 0.4 | $2.2M | NEW | 187k | 11.58 |
|
| Tango Therapeutics (TNGX) | 0.4 | $2.1M | +17% | 245k | 8.40 |
|
| Oric Pharmaceuticals (ORIC) | 0.4 | $2.0M | -17% | 167k | 12.00 |
|
| X4 Pharmaceuticals Com New (XFOR) | 0.4 | $1.9M | NEW | 555k | 3.42 |
|
| Pepgen (PEPG) | 0.3 | $1.8M | NEW | 389k | 4.62 |
|
| Assembly Biosciences Com New (ASMB) | 0.3 | $1.7M | NEW | 66k | 25.60 |
|
| Dianthus Therapeutics (DNTH) | 0.3 | $1.6M | NEW | 41k | 39.35 |
|
| Perceptive Cap Solutions Cor Cl A Ord Shs (PCSC) | 0.3 | $1.6M | 150k | 10.60 |
|
|
| Protara Therapeutics Com Stk (TARA) | 0.3 | $1.6M | -68% | 364k | 4.35 |
|
| Compass Pathways Sponsored Ads (CMPS) | 0.3 | $1.6M | NEW | 276k | 5.73 |
|
| Pyxis Oncology Common Stock (PYXS) | 0.3 | $1.5M | NEW | 690k | 2.22 |
|
| Arbutus Biopharma (ABUS) | 0.3 | $1.4M | NEW | 300k | 4.54 |
|
| Mbx Biosciences (MBX) | 0.3 | $1.3M | -46% | 75k | 17.50 |
|
| Adc Therapeutics Sa SHS (ADCT) | 0.2 | $1.1M | 283k | 4.00 |
|
|
| Arcellx Common Stock (ACLX) | 0.2 | $934k | -94% | 11k | 82.10 |
|
| Mind Medicine Mindmed Com New (MNMD) | 0.2 | $906k | -15% | 77k | 11.79 |
|
| Enanta Pharmaceuticals (ENTA) | 0.2 | $900k | NEW | 75k | 11.97 |
|
| Zenas Biopharma (ZBIO) | 0.2 | $860k | NEW | 39k | 22.20 |
|
| Aadi Bioscience (WHWK) | 0.2 | $806k | NEW | 424k | 1.90 |
|
| Corvus Pharmaceuticals (CRVS) | 0.1 | $711k | NEW | 96k | 7.37 |
|
| Kalvista Pharmaceuticals (KALV) | 0.1 | $692k | -85% | 57k | 12.18 |
|
| Meiragtx Holdings (MGTX) | 0.1 | $674k | NEW | 82k | 8.23 |
|
| Terns Pharmaceuticals (TERN) | 0.1 | $673k | NEW | 90k | 7.51 |
|
| Arcturus Therapeutics Hldg I (ARCT) | 0.1 | $656k | NEW | 36k | 18.43 |
|
| Spdr Series Trust S&p Biotech Put Option (XBI) | 0.1 | $596k | NEW | 1.5M | 0.40 |
|
| Ventyx Biosciences (VTYX) | 0.1 | $521k | NEW | 168k | 3.11 |
|
| Atai Life Sciences Nv SHS (ATAI) | 0.1 | $402k | NEW | 76k | 5.29 |
|
| Clearpoint Neuro (CLPT) | 0.1 | $363k | NEW | 17k | 21.79 |
|
| Adagio Therapeutics (IVVD) | 0.1 | $307k | NEW | 279k | 1.10 |
|
| Inventiva Sa Ads (IVA) | 0.0 | $179k | NEW | 31k | 5.79 |
|
| Ionis Pharmaceuticals Call Option (IONS) | 0.0 | $138k | NEW | 50k | 2.75 |
|
| Crispr Therapeutics Namen Akt Call Option (CRSP) | 0.0 | $59k | NEW | 40k | 1.48 |
|
| Ark Etf Tr Genomic Rev Etf Call Option (ARKG) | 0.0 | $30k | NEW | 200k | 0.15 |
|
Past Filings by Stempoint Capital
SEC 13F filings are viewable for Stempoint Capital going back to 2024
- Stempoint Capital 2025 Q3 filed Nov. 14, 2025
- Stempoint Capital 2025 Q2 filed Aug. 14, 2025
- Stempoint Capital 2025 Q1 filed May 15, 2025
- Stempoint Capital 2024 Q4 filed Feb. 14, 2025
- Stempoint Capital 2024 Q3 filed Nov. 13, 2024
- Stempoint Capital 2024 Q2 restated filed Aug. 13, 2024
- Stempoint Capital 2024 Q1 restated filed Aug. 9, 2024